{"slideshow_credits": null, "snippet": "Teva\u2019s $40.5 billion deal for the generic drug business of Allergan was approved after they agreed to sell some operations to ease antitrust concerns.", "abstract": "European Union approves $40.5 billion sale of Allergan to Teva Pharmaceutical Industries after companies agreed to sell some businesses; United States still needs to approve deal. ", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Chad", "role": "reported", "lastname": "BRAY", "rank": 1, "organization": ""}], "original": "By CHAD BRAY"}, "web_url": "http://www.nytimes.com/2016/03/11/business/dealbook/eu-approves-teva-allergan-deal-with-conditions.html", "lead_paragraph": "Teva\u2019s $40.5 billion deal for the generic drug business of Allergan was approved after they agreed to sell some operations to ease antitrust concerns.", "headline": {"main": "E.U. Approves Teva-Allergan Deal With Conditions", "print_headline": "Business Briefing; Europe Approves Teva Deal to Buy Allergan Generics"}, "_id": "56e196a438f0d80718d56abb", "word_count": "260", "multimedia": [], "pub_date": "2016-03-11T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Teva Pharmaceutical Industries Ltd", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Allergan Inc", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "European Union", "is_major": "N", "rank": "3"}, {"name": "organizations", "value": "European Commission", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Generic Brands and Products", "is_major": "N", "rank": "6"}, {"name": "subject", "value": "Antitrust Laws and Competition Issues", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}